Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR6390 plus Nab-paclitaxel and Gemcitabine in advanced pancreatic cancer
NCT05185869Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- Jan 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dalpiciclib in pancreatic ductal adenocarcinoma (PDAC), sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
dalpiciclib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05185869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05185869.